GDTC — CytoMed Therapeutics Limited
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: SG
- Exchange: NASDAQ
- Employees: 43
- Website: https://w2.cytomed.sg
Latest SEC filings for GDTC
- 6-K — 2026-09-30
- 6-K — 2026-06-23
- 6-K — 2026-05-15
- 6-K — 2026-05-11
- 6-K — 2026-04-14
- 20-F — 2026-03-31
- 6-K — 2026-03-31
- 6-K — 2026-01-28
- 6-K — 2026-01-13
- 6-K — 2025-12-08
Latest GDTC news
- — CytoMed Therapeutics receives Nasdaq notice over minimum bid price deficiency (seekingalpha_market)
Educational tool only — not investment advice.